Literature DB >> 23933908

Loss of COP1 expression determines poor prognosisin patients with gastric cancer.

Genta Sawada1, Hiroki Ueo, Tae Matsumura, Ryutaro Uchi, Masahisa Ishibashi, Kosuke Mima, Junji Kurashige, Yusuke Takahashi, Sayuri Akiyoshi, Tomoya Sudo, Keishi Sugimachi, Yuichiro Doki, Masaki Mori, Koshi Mimori.   

Abstract

Previous studies have suggested conflicting roles for the E3 ubiquitin ligase COP1 in tumorigenesis, providing evidence that both the oncoprotein c-Jun and the tumor suppressor p53 may be COP1 targets. In the present study, we focused on the clinical significance of COP1 expression in gastric cancer cases and analyzed the malignant behavior of COP1‑knockdown gastric cancer cells in vitro. We analyzed COP1 expression in cancer lesions and the corresponding normal mucosa to demonstrate the clinical significance of COP1 expression in 133 cases of gastric cancer. We also investigated the relationship between COP1 expression and cell proliferation and the association of COP1 with c‑Jun transcriptional target genes, such as MMP1, MMP7 and MMP10. The expression of COP1 mRNA was significantly lower in gastric cancer tissues compared to the corresponding normal mucosa (P=0.049). In multivariate analysis for overall survival, we found that COP1 expression was an independent prognostic factor in gastric cancer. Knockdown of COP1 expression in the gastric cancer cell lines MKN‑45 and NUGC4 promoted proliferation, and significant associations between COP1 expression and MMP1, MMP7 and MMP10 were also observed in knockdown assays. In conclusion, the present study suggests that loss of COP1 expression may be a novel indicator for the biological aggressiveness in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23933908     DOI: 10.3892/or.2013.2664

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

Review 1.  Ubiquitin proteasome system research in gastrointestinal cancer.

Authors:  Jia-Ling Zhong; Chang-Zhi Huang
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

Review 2.  Role of E3 ubiquitin ligases in gastric cancer.

Authors:  Ya-Chao Hou; Jing-Yu Deng
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 3.  The role of cullin proteins in gastric cancer.

Authors:  Peng Chen; Guo-Dong Yao
Journal:  Tumour Biol       Date:  2015-10-15

4.  Correlation of constitutive photomorphogenic 1 (COP1) and p27 tumor suppressor protein expression in ovarian cancer.

Authors:  Eun-Ji Ko; Young Lim Oh; Heung Yeol Kim; Wan Kyu Eo; Hongbae Kim; Ki Hyung Kim; Suk Bong Koh; Mee Sun Ock; Yung Hyun Choi; Ari Kim; Hyun Ho Choi; Eun Joo Park; Hee-Jae Cha
Journal:  Genes Genomics       Date:  2019-04-26       Impact factor: 1.839

5.  Overexpression of E3 ubiquitin ligase tripartite motif 32 correlates with a poor prognosis in patients with gastric cancer.

Authors:  Masahiro Ito; Kazuhiro Migita; Sohei Matsumoto; Kohei Wakatsuki; Tetsuya Tanaka; Tomohiro Kunishige; Hiroshi Nakade; Mitsuhiro Nakatani; Yoshiyuki Nakajima
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

Review 6.  Regulation of the DNA damage response by ubiquitin conjugation.

Authors:  Kerstin Brinkmann; Michael Schell; Thorsten Hoppe; Hamid Kashkar
Journal:  Front Genet       Date:  2015-03-10       Impact factor: 4.599

7.  Epigenetic profiling of human brain differential DNA methylation networks in schizophrenia.

Authors:  Sheng-An Lee; Kuo-Chuan Huang
Journal:  BMC Med Genomics       Date:  2016-12-05       Impact factor: 3.063

8.  Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma.

Authors:  Mengjie Guo; Pinggang Ding; Zhen Zhu; Lu Fan; Yanyan Zhou; Shu Yang; Ye Yang; Chunyan Gu
Journal:  Front Cell Dev Biol       Date:  2021-04-21

9.  The prognosis analysis of RFWD2 inhibiting the expression of ETV1 in colorectal cancer.

Authors:  Wei Huang; Xiumei Tian; Xiaoying Guan
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.